StocksExact Sciences CorpEXAS

EXAS

Exact Sciences Corp

127.94 0.28 (0.22%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
127.88
B
128.22

Overview

Prev Close127.94
Day's Range126.94 - 129.57
52 Week Range70.63 - 158.50
Average Volume (3m)1.48M
1-Year Return44.06%
Beta1.247
Market Cap21.95B
P/E Ratio
Revenue1.55B
EPS-5.0153
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.712/01/202125/03/202103/06/2021100.00110.00120.00130.00140.00150.00160.00
Chart times in UTC
Industry Biotechnology
CEO Kevin T. Conroy
Employees 5,000

FINANCIAL SUMMARY

For the quarter ended 31/3/2021, Exact Sciences Corp's revenues decreased by 13.78% and amounted to 402.08M. Net income increased by 92.87% to -31.16M. Net assets increased by 29.24% to 3.65B and EPS increased from -2.79 to -0.18.
EXAS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
69.21%
Net Profit Margin
-63.26%
Operating Margin
-24.41%
Return On Investment
-21.21%
06/20
09/20
12/20
03/21
Total Revenue
268.87M
408.36M
466.34M
402.08M
Gross Profit
167.55M
289.87M
343.38M
268.89M
Operating Income
-90.67M
6.33M
-2.7M
-290.24M
Net Income
-86.14M
-219.88M
-436.81M
-31.16M